Axsome Therapeutics

CNS Pipeline Advancements Will Expand Global Reach

AnalystConsensusTarget

Not Invested

Consensus Narrative from 19 Analysts

Published

28 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$176.95

33.0% undervalued

15 Aug

US$118.51

33.9%

6.6%

Author's Valuation

US$176.9

33.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Increased 0.089%

AnalystConsensusTarget Fair Value

US$176.9

33.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

34.26%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$578.84m

Earnings '28

20.84x

PE Ratio '28

US$12.06b

Market Cap '28

US$12.06b

Market Cap '28

56.07m

No. shares '28

US$215.14

Share Price '28

US$215.14 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$176.73

Fair Value '25

CNS Pipeline Advancements Will Expand Global Reach

Shared on01 May 25Fair value Increased 0.089%

Shared on01 May 25
Fair value Increased 0.089%